3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP
together with gemcitabine in treating patients with advanced solid tumors or lymphoma. Drugs
used in chemotherapy, such as 3-AP and gemcitabine (GEM), work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. 3-AP
may help gemcitabine kill more cancer cells by making the cells more sensitive to the drug.
3-AP may also stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.